Instruction 1(b)

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  Levine Mark S.  (Last) (First) (Middle)  C/O MINERVA NEUROSCIENCES, INC.  1601 TRAPELO ROAD, SUITE 284 |   |  |  |         |  | Issuer Name and Ticker or Trading Symbol     Minerva Neurosciences, Inc. [ NERV ]  3. Date of Earliest Transaction (Month/Day/Year) 12/14/2016 |  |              |   |   |                               |                 |                                       |                                   | Relationship of Reporting Person(s) to Issuer neck all applicable)  Director  Difficer (give title below)  SVP,General Counsel & Sec. |  |                                   |  | ner<br>pecify                         |  |
|--|---|--|--|---------|--|--|--|--------------|---|---|-------------------------------|-----------------|---------------------------------------|-----------------------------------|---|--|-----------------------------------|--|---------------------------------------|--|
| (Street) WALTHAM MA 02451  |   |  |  |         | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |  |              |   |   |                               |                 |                                       | ine)<br>X                         | , ·   |  |                                   |  |                                       |  |
| (City) (State) (Zip)   |   |  |  |         |  |  |  |              |   |   |                               |                 |                                       |                                   | 1 (1301)  |  |                                   |  |                                       |  |
|  |   | Tab  | le I - Non   | -Deriva | ative  | e Se   | curities   | s Ac         | quired, D   | isp   | osed o                        | f, or Be        | nefici                                | ally                              | Owned   |  |                                   |  |                                       |  |
| Date   |   |  | 2. Transa<br>Date<br>(Month/D                      |         | ar)  | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Yea  |  | Code (Instr. |   | 4. Securities Acquired (A)<br>Disposed Of (D) (Instr. 3, 5) |                               |                 |                                       | Securitie<br>Beneficia<br>Owned F | 5. Amount of<br>Securities<br>Beneficially<br>Dwned Following   |  | : Direct<br>r Indirect<br>str. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership                      |                                       |  |
|  |   |  |  |         |  |  |  |              | Code  | , l   | Amount                        | (A) o<br>(D)    | r Pric                                | е                                 | Reported<br>Transact<br>(Instr. 3 a   | ion(s)   |                                   |  | (Instr. 4)                            |  |
|  |   | -  | Fable II - [                                       |         |  |  |  |              | uired, Dis<br>, options                                 |   |                               |                 |                                       |                                   | wned  |  | ,                                 | ,  |                                       |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution D<br>if any<br>(Month/Day/ | ate, T  | Transaction<br>Code (Instr.                              |  | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D) (Instr.<br>3, 4 and 5) |              | 6. Date Exercisal<br>Expiration Date<br>(Month/Day/Year |   | of Secu<br>Underly<br>Derivat |                 | Securities<br>derlying                |                                   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | 9. Numbe<br>derivative<br>Securities<br>Beneficia<br>Owned<br>Following<br>Reported<br>Transacti<br>(Instr. 4) | e<br>S<br>Illy                    | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4) |  |
|  |   |  |  | c       | code   | v  | (A)  | (D)          | Date<br>Exercisable                                     |   | piration<br>te                | Title           | Amour<br>or<br>Number<br>of<br>Shares | er                                |   |  |                                   |  |                                       |  |
| Restricted<br>Stock<br>Units   | (1)   | 12/14/2016                                 |  |         | A  |  | 20,000   |              | (2)   |   | (2)                           | Common<br>Stock | 20,00                                 | 00                                | \$0.00  | 20,00  | 0                                 | D  |                                       |  |
| Employee<br>Stock<br>Option<br>(Right to   | \$13.45 <sup>(3)</sup>  | 12/14/2016                                 |  |         | A  |  | 35,000   |              | (4)   | 12/   | /13/2026                      | Common<br>Stock | 35,00                                 | 00                                | \$0.00  | 35,00  | 0                                 | D  |                                       |  |

## **Explanation of Responses:**

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock
- 2. Represents shares issuable upon the vesting of restricted stock units ("RSUs") awarded to the Reporting Person on December 14, 2016. The RSUs vest in 4 equal annual installments beginning on December 14, 2017 and will be fully vested on December 14, 2020, in all cases so long as there has been no break in the Reporting Person's continuous service through such date.
- 3. The exercise price is the closing price of the Issuer's common stock on December 14, 2016.
- 4. This option shall vest as follows: 25% on December 14, 2017 and then in quarterly installments over 3 years thereafter.

## Remarks:

12/16/2016 /s/ Mark Levine

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.